Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 12, 2021

SELL
$29.97 - $37.17 $1.03 Million - $1.28 Million
-34,500 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$45.06 - $67.74 $135,180 - $203,219
3,000 Added 9.52%
34,500 $1.56 Million
Q1 2020

May 14, 2020

BUY
$40.01 - $73.97 $104,026 - $192,322
2,600 Added 9.0%
31,500 $1.5 Million
Q4 2019

Feb 14, 2020

SELL
$37.13 - $74.62 $74,260 - $149,240
-2,000 Reduced 6.47%
28,900 $2.07 Million
Q3 2019

Nov 14, 2019

BUY
$39.36 - $76.8 $129,888 - $253,440
3,300 Added 11.96%
30,900 $1.22 Million
Q2 2019

Aug 14, 2019

SELL
$52.76 - $82.19 $564,532 - $879,433
-10,700 Reduced 27.94%
27,600 $2.16 Million
Q1 2019

May 15, 2019

BUY
$27.39 - $68.41 $775,137 - $1.94 Million
28,300 Added 283.0%
38,300 $2.29 Million
Q4 2018

Feb 12, 2019

SELL
$22.8 - $33.93 $225,720 - $335,907
-9,900 Reduced 49.75%
10,000 $288,000
Q3 2018

Nov 13, 2018

SELL
$29.75 - $43.08 $8,925 - $12,924
-300 Reduced 1.49%
19,900 $724,000
Q2 2018

Aug 07, 2018

BUY
$21.96 - $39.94 $443,592 - $806,788
20,200 New
20,200 $764,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $300M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Bellevue Group Ag Portfolio

Follow Bellevue Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Bellevue Group Ag with notifications on news.